Document is current
Any future updates will be listed below
-
Authors
Sánchez, Pedro
Álamo, Cecilio
Almendros, Marcos
Schlueter, Max
Tasoulas, Anastasios
Martínez, Javier
-
Funding
Funding for this research was provided by:
Laboratorios Farmacéuticos Rovi, S.A.
- License Information
-
More Information
Article History
Received: 23 June 2023
Accepted: 22 August 2023
First Online: 2 September 2023
Declarations
:
: Not applicable.
: Not applicable.
: P.S. has received personal fees from Janssen-Cilag, Lundbeck, Otsuka, Casen-Recordati, Angelini, Adamed, Exeltis, Osakidetza, Ferrer, Rovi, and grants from Instituto de Salud Carlos III. C.A. has participated in the last 5 years as a consultant and/or speaker in training activities related to Neuropsychopharmacology organized by the following companies: Adamed, Angelini, Casen-Recordati, Exeltis, Ferrer, Grunenthal, Indivior, Italdrug, Janssen-Cilag, Juste SAQF, Kyowa Kirin, Lundbeck, Mundipharma, Neuraxpharm, Normon, Novartis, Otsuka, Pfizer, Roche, Rovi, Rubió, Servier and Takeda-Shire. M.A. and J.M. are employees of Laboratorios Farmacéuticos Rovi, S.A., the sole developer of Risperidone ISM<sup>®</sup>. M. S. and A.T. are full-time employees of IQVIA, who were commissioned by Laboratorios Farmacéuticos Rovi, S.A. for the conduct of this analysis.
